Protara Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Good morning, everyone, and welcome back to H.C. Wainwright's 25th Annual Global Investment Conference. My name is Andres Maldonado. I'm a biotech analyst here at the firm, and I'd like to introduce our next presenter. I'd like to welcome Jesse Shefferman, who's the CEO of Protara Therapeutics. Welcome, and the floor is yours.
Thank you very much, and thanks to the H.C. Wainwright team for having Protara here. I'm going to try and move quickly through a lot of material here. We've got a short amount of time.
A quick introduction on Protara Therapeutics. We are a New York City-based biotechnology company focused on oncology and rare diseases. We have three programs across our portfolio. Our lead asset is TARA-002. It is a bacterial immunopotentiator first developed in the 1970s in Japan, which we are now repurposing for non-muscle-invasive bladder cancer as well as a rare structural malformations disorder called lymphatic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
